Trial Profile
An open label, prospective, single center, observational study assessing clinical outcomes in Type 2 Diabetes Mellitus patients switched to IDeglira (Insulin degludec/Liraglutide)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 May 2017
Price :
$35
*
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- 19 May 2017 New trial record
- 01 Apr 2017 Results published in the Diabetes Therapy